MARKET

FLXN

FLXN

Flexion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.23
-0.22
-3.41%
After Hours: 6.25 +0.02 +0.32% 16:43 09/17 EDT
OPEN
6.42
PREV CLOSE
6.45
HIGH
6.53
LOW
6.19
VOLUME
4.84M
TURNOVER
--
52 WEEK HIGH
13.66
52 WEEK LOW
4.300
MARKET CAP
313.32M
P/E (TTM)
-3.2529
1D
5D
1M
3M
1Y
5Y
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright...
GlobeNewswire · 09/08 20:30
COUP, FLXN, CYXT and MGNX among after hours movers
Gainers: COUP +5.6%. FLXN +4.3%. BIDU +3.8%. UPST +2.8%. GO +2.3%. Losers: CYXT -8.0%. MGNX -7.5%. WBA -6.7%. MRVI -5.6%. UAL -5.0%.
Seekingalpha · 09/07 21:29
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtu...
GlobeNewswire · 09/03 13:00
BRIEF-Flexion Therapeutics Says Zilretta Included In AAOS Clinical Practice Guidelines For Knee Osteoarthritis
reuters.com · 09/02 11:36
Flexion Therapeutics Reports Inclusion Of ZILRETTA In American Academy Of Orthopaedic Surgeons Clinical Practice Guidelines For Mgmt. Of Osteoarthritis Of The Knee
Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based
Benzinga · 09/02 11:32
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee
AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) ann...
GlobeNewswire · 09/02 11:30
Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know
Flexion Therapeutics (FLXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks · 08/30 16:00
Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?
Flexion Therapeutics Inc (NASDAQ: FLXN) expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy. 
Benzinga · 08/25 17:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FLXN. Analyze the recent business situations of Flexion through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FLXN stock price target is 18.00 with a high estimate of 27.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 203
Institutional Holdings: 48.71M
% Owned: 96.84%
Shares Outstanding: 50.29M
TypeInstitutionsShares
Increased
60
5.20M
New
19
1.08M
Decreased
36
2.40M
Sold Out
23
5.67M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Patrick Mahaffy
President/Chief Executive Officer/Director
Michael Clayman
Chief Financial Officer/Chief Accounting Officer
Frederick Driscoll
General Counsel/Secretary
Mark Levine
Executive Officer
Adam Muzikant
Other
Melissa Layman
Other
Kerry Wentworth
Other
Christina Willwerth
Director
Utpal Koppikar
Independent Director
Scott Canute
Independent Director
Samuel Colella
Independent Director
Elizabeth Kwo
Independent Director
Heath Lukatch
Independent Director
C. Ann Merrifield
Independent Director
Alan Milinazzo
Independent Director
Mark Stejbach
No Data
  • All
  • Financials
  • Insiders
More
About FLXN
Flexion Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis. Its product candidate, ZILRETTA, is the intra-articular (IA) injection indicated for the management of OA knee pain. It is approved by Food and Drug Administration (FDA) to manage osteoarthritis knee pain. The ZILRETTA is a non-opioid therapy that employs its microsphere technology to provide pain relief. It markets ZILRETTA to prescribing physicians through its own field sales force of Musculoskeletal Business Managers (MBMs). The Company's other product candidates include FX201 and FX301. The FX201 is an IA gene therapy product candidate in clinical development for the treatment of OA. The FX301 is developed as a locally administered peripheral analgesic nerve block for management of post-operative pain.

Webull offers kinds of Flexion Therapeutics Inc stock information, including NASDAQ:FLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLXN stock methods without spending real money on the virtual paper trading platform.